A previous clinical study indicated that patients with HER2 positive breast cancer are more likely to achieve pathologic complete response to Taxol/Fluorouracil-Adriamycin-Cyclophosphamide (T/FAC) NAC5. Here, ERBB2 is linked to breast carcinoma.